Bristol-Myers Squibb GmbH & Co. KGaA

Arnulfstr. 29 | 80636 München

Tel.: +49 89 1 21 42-0

www.bms-onkologie.de

 

Ausgewählte Pressemitteilungen

Nivolumab Plus Ipilimumab Combination Demonstrated Superior Overall Survival

CheckMate -214 Study Evaluating Nivolumab in Combination with Ipilimumab Stopped Early for Demonstrating Overall Survival Benefit

Themen: